176 related articles for article (PubMed ID: 26549456)
21. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.
Dziembowska M; Fondaneche MC; Vedrenne J; Barbieri G; Wiszniewski W; Picard C; Cant AJ; Steimle V; Charron D; Alca-Loridan C; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2002 Feb; 53(10-11):821-9. PubMed ID: 11862382
[TBL] [Abstract][Full Text] [Related]
22. CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression.
Rimsza LM; Chan WC; Gascoyne RD; Campo E; Jaffe ES; Staudt LM; Delabie J; Rosenwald A; Murphy SP
Haematologica; 2009 Apr; 94(4):596-8. PubMed ID: 19229048
[No Abstract] [Full Text] [Related]
23. [Major histocompatibility complex class II transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class II (MHC-II) expression in Jukart cells].
Guo R; Zou P; Song YP; Ma J; Lu HZ; Cao YL; Tong YJ
Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):925-8. PubMed ID: 14723817
[TBL] [Abstract][Full Text] [Related]
24. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation.
Viganò E; Gunawardana J; Mottok A; Van Tol T; Mak K; Chan FC; Chong L; Chavez E; Woolcock B; Takata K; Twa D; Shulha HP; Telenius A; Kutovaya O; Hung SS; Healy S; Ben-Neriah S; Leroy K; Gaulard P; Diepstra A; Kridel R; Savage KJ; Rimsza L; Gascoyne R; Steidl C
Blood; 2018 May; 131(18):2036-2046. PubMed ID: 29467182
[TBL] [Abstract][Full Text] [Related]
25. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels.
Schmetterer KG; Seidel MG; Körmöczi U; Rottal A; Schwarz K; Matthes-Martin S; Steinberger P; Pickl WF
Int Arch Allergy Immunol; 2010; 152(4):390-400. PubMed ID: 20197681
[TBL] [Abstract][Full Text] [Related]
26. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
27. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells.
Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C
J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519
[TBL] [Abstract][Full Text] [Related]
28. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter.
Choi YE; Yu HN; Yoon CH; Bae YS
Eur J Immunol; 2009 Mar; 39(3):858-68. PubMed ID: 19224634
[TBL] [Abstract][Full Text] [Related]
29. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
Rohn W; Tang LP; Dong Y; Benveniste EN
J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
[TBL] [Abstract][Full Text] [Related]
30. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.
Li G; Harton JA; Zhu X; Ting JP
Mol Cell Biol; 2001 Jul; 21(14):4626-35. PubMed ID: 11416140
[TBL] [Abstract][Full Text] [Related]
32. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
Broxmeyer HE; Cooper S; Hangoc G; Chang CH
Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
[TBL] [Abstract][Full Text] [Related]
33. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
[TBL] [Abstract][Full Text] [Related]
34. TNF-alpha suppresses IFN-gamma-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNA.
Han Y; Zhou ZH; Ransohoff RM
J Immunol; 1999 Aug; 163(3):1435-40. PubMed ID: 10415044
[TBL] [Abstract][Full Text] [Related]
35. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA.
Muhlethaler-Mottet A; Otten LA; Steimle V; Mach B
EMBO J; 1997 May; 16(10):2851-60. PubMed ID: 9184229
[TBL] [Abstract][Full Text] [Related]
36. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.
Twa DD; Chan FC; Ben-Neriah S; Woolcock BW; Mottok A; Tan KL; Slack GW; Gunawardana J; Lim RS; McPherson AW; Kridel R; Telenius A; Scott DW; Savage KJ; Shah SP; Gascoyne RD; Steidl C
Blood; 2014 Mar; 123(13):2062-5. PubMed ID: 24497532
[TBL] [Abstract][Full Text] [Related]
37. The major histocompatibility complex class II transactivator is differentially regulated by interferon-gamma and transforming growth factor-beta in microglial cells.
Pazmany T; Tomasi TB
J Neuroimmunol; 2006 Mar; 172(1-2):18-26. PubMed ID: 16360884
[TBL] [Abstract][Full Text] [Related]
38. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
[TBL] [Abstract][Full Text] [Related]
39. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.
Rimsza LM; Roberts RA; Campo E; Grogan TM; Bea S; Salaverria I; Zettl A; Rosenwald A; Ott G; Muller-Hermelink HK; Delabie J; Fisher RI; Unger JM; Leblanc M; Staudt LM; Jaffe ES; Gascoyne RD; Chan WC; Weisenburger DD; Greiner T; Braziel RM; Miller TP
Blood; 2006 Feb; 107(3):1101-7. PubMed ID: 16239429
[TBL] [Abstract][Full Text] [Related]
40. Downregulating immunogenicity of Schwann cells via inhibiting a potential target of class II transactivator (CIITA) gene.
Yang Y; Dai W; Chen Z; Yan Z; Yao Z; Zhang C
Biosci Trends; 2013 Feb; 7(1):50-5. PubMed ID: 23524893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
